Clinicopathological characteristics and recurrence risk in patients with ductal carcinoma in situ of the breast

Authors

  • Marcelo Hueb Cecilio Naves Bruno União das Faculdades dos Grandes Lagos, Advanced Research Center in Medicine – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0002-0000-5739
  • Vitor Hugo de Souza União das Faculdades dos Grandes Lagos, Advanced Research Center in Medicine – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0003-1795-1841
  • Leonardo Fleury Orlandini Universidade de São Paulo, Faculty of Medicine, Departmet of Gynecology and Obstetrics – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0002-7285-6081
  • Helio Humberto Angotti Carrara Universidade de São Paulo, Faculty of Medicine, Departmet of Gynecology and Obstetrics – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0003-1477-2805
  • Francisco José Candido dos Reis Universidade de São Paulo, Faculty of Medicine, Departmet of Gynecology and Obstetrics – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0001-5758-5917
  • Jurandyr Moreira de Andrade Universidade de São Paulo, Faculty of Medicine, Departmet of Gynecology and Obstetrics – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0003-3619-0582
  • Priscila Longhin Bosquesi União das Faculdades dos Grandes Lagos, Advanced Research Center in Medicine – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0003-0221-1488
  • Daniel Guimarães Tiezzi União das Faculdades dos Grandes Lagos, Advanced Research Center in Medicine – São José do Rio Preto (SP), Brazil. Universidade de São Paulo, Faculty of Medicine, Departmet of Gynecology and Obstetrics – São José do Rio Preto (SP), Brazil. https://orcid.org/0000-0002-2660-0093

DOI:

https://doi.org/10.29289/259453942023006

Keywords:

ductal carcinoma in situ, DCIS, local neoplasm recurrence, breast, prognoses

Abstract

ABSTRACT: Introduction: With the widespread adoption of mammographic screening for breast cancer, ductal carcinoma in situ (DCIS) has been detected more frequently. In developing countries, the prevalence of ductal carcinoma in situ is low due to the opportunistic nature of breast cancer screening. The aim of this study was to evaluate the clinicopathological characteristics and recurrence rate in a cohort of patients with ductal carcinoma in situ in Brazil. Methods: This study was an retrospective analysis of all 1,736 patients with non-metastatic breast cancer treated at a reference public hospital between 1999 and 2013. All data were collected from medical records and the descriptive statistics were performed to characterize the clinical and pathological features. Results: In the present cohort, we identified 102 (5.2%) patients with non-invasive breast neoplasms. Mean age at diagnosis was 54±12.7 years and most patients were treated with breast conserving surgery. There is a strong association between nuclear grade and the expression of estrogen and progesterone receptors in ductal carcinoma in situ. Ipsilateral and contralateral recurrence rates in 10 years were 7.2% and 2%, respectively. Conclusion: The pathological features of ductal carcinoma in situ diagnosed in Brazil are similar to those observed in patients diagnosed in countries following a systematic screening program, and the treatment in our patients achieves similar success compared with published data in high-income countries.

Downloads

Download data is not yet available.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. https://doi.org/10.3322/caac.21654

2. Gorringe KL, Fox SB. Ductal carcinoma in Situ biology, biomarkers, and diagnosis. Front Oncol. 2017;7:248. https://doi.org/10.3389/fonc.2017.00248

3. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, et al. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011;18(10):2873-8. https://doi.org/10.1245/s10434-011-1707-2

4. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170-8. https://doi.org/10.1093/jnci/djp482

5. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346-66. https://doi.org/10.1200/JCO.19.02309

6. Hwang ES. The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. J Natl Cancer Inst Monogr. 2010;2010(41):197-9. https://doi.org/10.1093/jncimonographs/lgq032

7. Davidson N, Gelber R, Piccart M, Pruneri G, Pritchard K, Ravdin P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;41:162-77. https://doi.org/10.1093/jncimonographs/lgq039

8. Solin LJ, Kurtz J, Fourquet A, Amalric R, Recht A, Bornstein BA, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14(3):754-63. https://doi.org/10.1200/JCO.1996.14.3.754

9. Barrio AV, Van Zee KJ. Controversies in the treatment of ductal carcinoma in situ. Annu Rev Med. 2017;68:197-211. https://doi.org/10.1146/annurev-med-050715-104920

10. Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;262(4):623-31. https://doi.org/10.1097/SLA.0000000000001454

11. Magario MB, Poli-Neto OB, Tiezzi DG, Angotti Carrara HH, Moreira de Andrade J, et al. Mammography coverage and tumor stage in the opportunistic screening context. Clin Breast Cancer. 2019;19(6):456-9. https://doi.org/10.1016/j.clbc.2019.04.014

12. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. https://doi.org/10.1200/JCO.2013.50.9984

13. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95. https://doi.org/10.1200/JCO.2009.25.6529

14. Abrahão KS, Bergmann A, Aguiar SS, Thuler LC. Determinants of advanced stage presentation of breast cancer in 87,969 Brazilian women. Maturitas. 2015;82(4):365-70. https://doi.org/10.1016/j.maturitas.2015.07.021

15. Vieira RAC, Biller G, Uemura G, Ruiz CA, Curado MP. Breast cancer screening in developing countries. Clinics (São Paulo). 2017;72(4):244-53. https://doi.org/10.6061/clinics/2017(04)09

16. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):139-41. https://doi.org/10.1093/jncimonographs/lgq027

17. Rosa DD, Bines J, Werutsky G, Barrios CH, Cronemberger E, Queiroz GS, et al. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). Breast Cancer Res Treat. 2020;183(3):749-57. https://doi.org/10.1007/s10549-020-05831-y

18. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998-2005. https://doi.org/10.1056/NEJMoa1206809

19. Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013;310(8):797-8. https://doi.org/10.1001/jama.2013.108415

20. Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51(16):2296-303. https://doi.org/10.1016/j.ejca.2015.07.017

21. Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797. https://doi.org/10.1136/bmjopen-2018-026797

22. Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study. Eur J Cancer. 2015;51(12):1497-510. https://doi.org/10.1016/j.ejca.2015.05.008

23. Hwang ES, Solin L. De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer. J Clin Oncol. 2020;38(20):2230-9. https://doi.org/10.1200/JCO.19.02888

24. Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, et al. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. Br J Cancer. 2019;120(11):1075-82. https://doi.org/10.1038/s41416-019-0436-3

25. van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121(4):285-92. https://doi.org/10.1038/s41416-019-0478-6

26. Acrux T, Athanazio D, Gaudêncio D, Rocha C. Ductal carcinoma in situ of the breast: correlation of architectural, cytological, IHC findings and recurrence analysis. J Bras Patol e Med Lab. 2020;56:1-8. https://doi.org/10.5935/1676-2444.20200018

27. Petrone I, Rodrigues FR, Fernandes PV, Abdelhay E. Immunohistochemical Biomarkers in Ductal Carcinoma in Situ. Open J Pathol. 2020;10:129-46. https://doi.org/10.4236/ojpathology.2020.104013

28. Perez AA, Rocha RM, Balabram D, Souza ÁS, Gobbi H. Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast. Clinics (Sao Paulo). 2013;68(5):674-8. https://doi.org/10.6061/clinics/2013(05)15

29. Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM. Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr. 2010;2010(41):113-6. https://doi.org/10.1093/jncimonographs/lgq024

30. Tiezzi DG, Orlandini FL, Carrara HHA, Cândido Dos Reis FJ, Andrade JM. Current Breast Cancer Screening Scenario in Brazil. Rev Bras Ginecol Obstet. 2019;41(11):633-5. https://doi.org/10.1055/s-0039-3399550

31. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443-8. https://doi.org/10.1093/jnci/djh069

32. McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709-15. https://doi.org/10.1200/JCO.2014.57.9029

33. Bhutiani N, Holland MM, Mercer MK, Donaldson M, Berry TS, McMasters KM, et al. Effect of the ductal carcinoma in situ margin consensus guideline implementation on re-excision rates, satisfaction, and cost. Ann Surg Oncol. 2021;28(12):7432-8. https://doi.org/10.1245/s10434-021-10120-z

34. Badve SS, Gökmen-Polar Y. Ductal carcinoma in situ of breast: update 2019. Pathology. 2019;51(6):563-9. https://doi.org/10.1016/j.pathol.2019.07.005

35. Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ. Decreasing recurrence rates for ductal carcinoma In Situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol. 2015;22(10):3273-81. https://doi.org/10.1245/s10434-015-4740-8

36. Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? Ann Surg Oncol. 2017;24(10):2889-97. https://doi.org/10.1245/s10434-017-5931-2

Downloads

Published

2026-03-13

How to Cite

Bruno, M. H. C. N., Souza, V. H. de, Orlandini, L. F., Carrara, H. H. A., Reis, F. J. C. dos, Andrade, J. M. de, … Tiezzi, D. G. (2026). Clinicopathological characteristics and recurrence risk in patients with ductal carcinoma in situ of the breast. Mastology, 33. https://doi.org/10.29289/259453942023006

Issue

Vol. 33 (2023)

Section

Original Articles

License

Copyright (c) 2026 Marcelo Hueb Cecilio Naves Bruno, Vitor Hugo de Souza, Leonardo Fleury Orlandini, Helio Humberto Angotti Carrara, Francisco José Candido dos Reis, Jurandyr Moreira de Andrade, Priscila Longhin Bosquesi, Daniel Guimarães Tiezzi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.